Trial Profile
A Phase 1b/2a Study to Assess the Safety, Tolerability, PK, and Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Patients With Metastatic Colorectal or Gastric Gastroesophageal Junction Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Vactosertib (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors MedPacto
- 23 Apr 2024 Planned End Date changed from 1 Aug 2023 to 31 Aug 2024.
- 23 Apr 2024 Planned primary completion date changed from 1 Jun 2021 to 31 May 2024.
- 15 Apr 2024 Intevention study model changed to parallel,no of arms has been increased to 3 , safety and tolerability end point added , inclusion and exclusion criteria has been changed.